Ferdinando Calabria1, Agostino Chiaravalloti2, Carmelo Cicciò3, Vincenzo Gangemi4, Domenico Gullà5, Federico Rocca5, Gianpasquale Gallo6, Giuseppe Lucio Cascini4, Orazio Schillaci7. 1. Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, Italian National Research Council, IBFM-CNR, Catanzaro, Italy. Electronic address: ferdinandocalabria@hotmail.it. 2. Department of Diagnostic and Molecular Imaging, Interventional Radiology and Radiotherapy, University Hospital "Tor Vergata", Rome, Italy. 3. Department of Diagnostic Imaging, Sacro Cuore Hospital "Don Calabria", Verona, Italy. 4. Department of Diagnostic Imaging, Nuclear Medicine Unit, Magna Graecia University, Catanzaro, Italy. 5. Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, Italian National Research Council, IBFM-CNR, Catanzaro, Italy. 6. Department of Medical and Surgical Sciences, Clinical Surgery and Endoscopy Unit, University "Magna Graecia" Medical School, Viale Europa, Catanzaro, Italy. 7. Department of Biomedicine and Prevention, University "Tor Vergata", Rome, Italy; IRCCS Neuromed, Pozzilli (IS), Italy.
Abstract
INTRODUCTION: The 11C/18F-choline is a PET/CT radiopharmaceutical useful in detecting tumors with high lipogenesis. 11C/18F-choline uptake can occur in physiological conditions or tumors. The knowledge of its bio-distribution is essential to recognize physiologic variants or diagnostic pitfalls. Moreover, few information are available on the bio-distribution of this tracer in female patients. Our aim was to discuss some documented 18F-choline PET/CT pitfalls in prostate cancer patients. Our secondary aim was to describe the 18F-choline bio-distribution in the female body. METHODS: We collected diagnostic pitfalls in three PET centers examining 1000 prostate cancer by 18F-choline PET/CT. All pitfalls were ensured by follow-up, imaging and/or histology. We also performed whole body 18F-choline PET/CT in 5 female patients. RESULTS: 169/1000 (16.9%) patients showed pitfalls not owing to prostate cancer. These findings were due to inflammation, benign tumors while, in 1% of examined patients, a concomitant neoplasm was found. In the female body, the breast showed low physiological uptake. CONCLUSIONS: The accurate knowledge of 18F-choline PET/CT bio-distribution and diagnostic pitfalls is essential. Correlative imaging and histological exam are often necessary to depict pitfalls. In women, the uptake in the breast is due to the physiological gradient of 18F-choline uptake in the exocrine glands. ADVANCES IN KNOWLEDGE: Our results confirm the possibility of 18F-choline uptake in several diseases other than prostate cancer. However, our experience was acquired on a large population and shows that a conspicuous amount of 18F-choline diagnostic pitfalls are easily recognizable and attributable to inflammation. A new advance in knowledge is the minimal difference in terms of physiological tracer bio-distribution between male and female patients. IMPLICATIONS FOR PATIENT CARE: The knowledge of the physiological bio-distribution and of the potential pitfalls linked of a tracer could help physicians to choose the best diagnostic and therapeutic approaches for a better patient quality of life.
INTRODUCTION: The 11C/18F-choline is a PET/CT radiopharmaceutical useful in detecting tumors with high lipogenesis. 11C/18F-choline uptake can occur in physiological conditions or tumors. The knowledge of its bio-distribution is essential to recognize physiologic variants or diagnostic pitfalls. Moreover, few information are available on the bio-distribution of this tracer in female patients. Our aim was to discuss some documented 18F-choline PET/CT pitfalls in prostate cancer patients. Our secondary aim was to describe the 18F-choline bio-distribution in the female body. METHODS: We collected diagnostic pitfalls in three PET centers examining 1000 prostate cancer by 18F-choline PET/CT. All pitfalls were ensured by follow-up, imaging and/or histology. We also performed whole body 18F-choline PET/CT in 5 female patients. RESULTS: 169/1000 (16.9%) patients showed pitfalls not owing to prostate cancer. These findings were due to inflammation, benign tumors while, in 1% of examined patients, a concomitant neoplasm was found. In the female body, the breast showed low physiological uptake. CONCLUSIONS: The accurate knowledge of 18F-choline PET/CT bio-distribution and diagnostic pitfalls is essential. Correlative imaging and histological exam are often necessary to depict pitfalls. In women, the uptake in the breast is due to the physiological gradient of 18F-choline uptake in the exocrine glands. ADVANCES IN KNOWLEDGE: Our results confirm the possibility of 18F-choline uptake in several diseases other than prostate cancer. However, our experience was acquired on a large population and shows that a conspicuous amount of 18F-choline diagnostic pitfalls are easily recognizable and attributable to inflammation. A new advance in knowledge is the minimal difference in terms of physiological tracer bio-distribution between male and female patients. IMPLICATIONS FOR PATIENT CARE: The knowledge of the physiological bio-distribution and of the potential pitfalls linked of a tracer could help physicians to choose the best diagnostic and therapeutic approaches for a better patient quality of life.
Authors: Manuel Scimeca; Nicoletta Urbano; Rita Bonfiglio; Sarah Natalia Mapelli; Carlo Vittorio Catapano; Giuseppina Maria Carbone; Sara Ciuffa; Mario Tavolozza; Orazio Schillaci; Alessandro Mauriello; Elena Bonanno Journal: Contrast Media Mol Imaging Date: 2018-12-09 Impact factor: 3.161
Authors: Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini Journal: Diagnostics (Basel) Date: 2021-05-11
Authors: Erika Di Zazzo; Giovanni Galasso; Pia Giovannelli; Marzia Di Donato; Antonio Bilancio; Bruno Perillo; Antonio A Sinisi; Antimo Migliaccio; Gabriella Castoria Journal: Cancers (Basel) Date: 2019-09-23 Impact factor: 6.639
Authors: Teodoro Rudolphi-Solero; Eva María Triviño-Ibáñez; Antonio Medina-Benítez; Javier Fernández-Fernández; Daniel José Rivas-Navas; Alejandro José Pérez-Alonso; Manuel Gómez-Río; Tarik Aroui-Luquin; Antonio Rodríguez-Fernández Journal: Diagnostics (Basel) Date: 2021-12-27